AHFS DI Essentials Users Guide
Name: AHFS DI Essentials Users Guide
- AHFS DI Essentials Users Guide dosage
- AHFS DI Essentials Users Guide dosage forms
- AHFS DI Essentials Users Guide uses
- AHFS DI Essentials Users Guide other uses for
- AHFS DI Essentials Users Guide tablet
- AHFS DI Essentials Users Guide drug
- AHFS DI Essentials Users Guide action
- AHFS DI Essentials Users Guide effects of
- AHFS DI Essentials Users Guide adverse effects
- AHFS DI Essentials Users Guide the effects of
- AHFS DI Essentials Users Guide therapeutic effect
- AHFS DI Essentials Users Guide brand name
- AHFS DI Essentials Users Guide names
- AHFS DI Essentials Users Guide injection
Organization of the Content
Since 1959, the American Society of Health-System Pharmacists (ASHP) has been building its evidence-based foundation for safe and effective drug therapy through its premier drug compendiumAHFS Drug Information. With AHFS DI Essentials™, ASHP continues to build on that foundation by providing a resource that focuses on the essential, evidence-based information that will allow pharmacists, nurses, physicians, and other health-care providers to access quickly, in a straight-forward fashion, the specific guidance needed to safely and effectively prescribe and monitor drug therapy. Because it is derived from the authoritative AHFS DI, the well-respected information development process, evidence analysis, and expert advice of authoritative reviewers are encapsulated and summarized in the new highly structured format of Essentials™.
AHFS DI Essentials™ monographs are written principally on single-drug entities; information on various trademarked preparations and brands of a drug is contained in a single monograph. Drug combinations are described in the monographs on the principal ingredients or, rarely, appear as separate monographs (e.g., Co-trimoxazole, Levodopa/Carbidopa) when the combinations are considered important because of therapeutic rationale and/or frequency of use.
AHFS DI Essentials™ is designed to offer clinicians easy access to knowledge that is critical at the point of care. Essentials™ monographs draw on the meticulously evidence-based guidance from the full AHFS DI database, distilling for the clinician the essential information on prescription and key over-the-counter (OTC) drugs in an easy-to-use, highly structured outline format.
Clinically important information that is needed to help clinicians provide safe and effective drug therapy is included. AHFS DI Essentials™ is not intended to provide the “full disclosure” safety information provided by US Food and Drug Administration (FDA)-approved professional labeling. Instead, it provides a summary of critical information intended to provide quick, point-of-care answers to common prescribing and monitoring questions. More detailed information generally can be found in the full-length AHFS DI monographs also published by ASHP (see for information on subscribing to this resource) and the manufacturers’ professional labeling. Users should refer to these resources for more complete information. Information on multiple products containing the same drug (either singly or in combination) often is included in the same Essentials™ monograph, incorporating key elements from a variety of professional labeling and other references (e.g., authoritative therapeutic guidelines).
Essentials™ monographs also include information that is outside the manufacturers’ labeling (“off-label,” “unlabeled”). This information is drawn from the full AHFS DI database, which is widely trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers.
Essentials™ includes a subset of drugs from the full AHFS DI database. Drugs were selected from those most widely used in hospital (including most parenteral drugs) and outpatient (including key OTC products) settings, new molecular entities (NMEs) introduced into the US market over the past 6 years, and drugs requiring particular attention for safe use (e.g., those with boxed warnings).
The presence or absence of a particular drug or use should not be interpreted as indicating any judgment by AHFS DI on its merits.
AHFS DI Essentials™ is designed to serve as an aid to, not a substitute for, sound, informed clinical judgment.
Organization of Full-length Monographs
Information within each drug monograph is divided into the following sections and subsections:
Monograph Title and Introductory Information
Class (AHFS and VA)
Brands (common brand names)
Specific Indications (Diseases/Conditions)
Dosage and Administration
Rate of Administration
Specific Indications (Diseases/Conditions)
Specific Indications (Diseases/Conditions)
Common Adverse Effects
Specific Drugs, Foods, and Tests (alphabetically)
Extent (e.g., placental, lactation, blood-brain barrier)
Plasma Protein Binding
Specific Dosage Forms
Actions and Spectrum
Advice to Patients
Generic Drug Name (Single-entity or Combination)
Dosage Forms (alphabetically)
Strength/Concentration (in ascending order)
Product Listings (alphabetically by Brand Names & Manufacturers)
Monograph Footnotes (e.g., off-label use footnote)
Copyright Notice, Selected Revision Date
Not all sections or subsections are included in each monograph. The information is divided only when applicable and necessary. Other subsections not listed above also are used within section.
Described below are the types of information that may be included in each major section and subsection within a monograph. Individual monographs may not contain all of the information described below, and the absence of specific information within an individual monograph does not imply that such information is unavailable.
Monograph Title and Introductory Information
Lists the USAN name or other name for the drug(s) described; the title includes only the base drug name.
If multiple forms (e.g., salts, esters) of the same drug are available, information about the forms is described throughout the monograph, where applicable. The specific various forms are listed as headings within the Preparations section, with the respective products described under each associated heading.
Occasionally, when several drug entities are described in a single monograph, an alternative title descriptive of the group (e.g., Antacids) is used. Specific drug entries for these groups with appropriate cross-references to the associated monograph appear alphabetically in the drugs listings.
Provides a brief chemical, structural, and/or pharmacologic/therapeutic description for the purpose of orientation and introduction.
Lists the applicable AHFS and VA pharmacologic and therapeutic classes for the drug. Occasionally, multiple classes for the same drug appear.
A listing of the AHFS Pharmacologic-Therapeutic Classification is included in the Appendix.
Lists common brand (trade) names for single-entity and combination products alphabetically. By comparison in the Preparations section, the brand names are listed with each specific product description, which are organized by ingredients, route, formulation, and strength.
Lists common synonyms, acronyms, former names, and other names for the drug.
Describes information required by FDA to appear in a prominently displayed box in the manufacturer’s professional labeling (prescribing information).
FDA currently is unable to provide a list of all drugs requiring such warnings. As a result, while a reasonable attempt was made to include these warnings in a box at the beginning of the respective Essentials™ monograph, the information occasionally may appear elsewhere in the monograph (e.g., in the Warnings section) or not at all.
Boxed Warning information describes special problems, particularly those that may lead to death or serious injury.
Although such boxed warnings usually appear at the beginning of labeling, they can appear anywhere in the manufacturer’s labeling at FDA’s prerogative.
Provides information on uses included in the labeling approved by FDA and those that are not ([“off-label”], unlabeled uses).
“Off-label” uses are identified with daggers† within the text of the monograph; a footnote that describes the use as such appears at the end of the monograph.
Comparisons with other forms of therapy and limitations on use are included when appropriate.
The Uses section is subdivided by major indication (disease/condition).
Under the Federal Food, Drug, and Cosmetic (FD&C) Act, the labeling approved by FDA for a drug is limited to those uses for which the sponsor has submitted information regarding the safety and efficacy of that product and which information has been reviewed by the FDA; other uses for which the sponsor has chosen not to submit data to the FDA may be demonstrated in the clinical literature before and after the product is approved by FDA. The FD&C Act does not, however, limit the manner in which a clinician may use an approved drug. Once a drug has been approved for marketing, the clinician may prescribe it for uses or in treatment regimens or patient populations (e.g., children) that are not included in approved labeling.
Such “off-label” uses may be appropriate and rational, and may reflect approaches to drug therapy that have been reported extensively in the medical literature. Valid new uses for drugs often are first discovered via serendipitous observations and therapeutic innovations, and then subsequently may be confirmed by well-designed and controlled studies. Inclusion of such new uses in the FDA-approved labeling for a drug may take considerable time and, without the initiative of the manufacturer whose product is involved, may never occur. Therefore, accepted medical practice (state-of-the-art) often includes drug use that is not included in FDA-approved labeling.
AHFS DI Essentials™ monographs include the principal “off-label” uses developed for the full AHFS DI database via its respected evidence-based process. Coverage of “off-label” uses in AHFS DI monographs has been recognized by the US Congress (e.g., in OBRA 90, OBRA 93), federal agencies and programs (e.g., CMS; under part 456 of CMS regulations governing utilization control for Medicaid and under section 1927 of the Social Security Act), third-party health-care providers, and others (e.g., Health Insurance Association of America [HIAA], National Blue Cross and Blue Shield Association, National Association of Insurance Commissioners), designating it through legislation, regulation, and other official guidance documents as an “official” compendium for information on medically accepted uses of drugs.
Drugs designated as orphan drugs by FDA and those otherwise considered as orphans are described. An orphan drug is one that is used for the treatment of a rare disease or condition that either occurs in fewer than 200,000 individuals in the US or is more prevalent but for which there is no reasonable expectation that the cost of developing and marketing the drug in the US for such disease or condition would be recovered from US sales.
Dosage and Administration
Includes information on the various applicable routes of administration for specific dosage forms of a drug and on its reconstitution, dilution, and administration. Also includes information on various applicable dosages and regimens.
The Administration subsection describes the routes of administration and, when necessary for clarity, the appropriate dosage form for each route. Instructions for administering the drug (e.g., after meals, with food) and specialized methods of administration are given.
Occasionally, instructions for extemporaneous preparation of a dosage form that is not commercially available (e.g., preparation of a pediatric oral suspension from the contents of capsules) are included.
In addition to information described for the Administration subsection, instructions for reconstitution and, when applicable, further dilution of the dosage form are presented. The rate of injection or infusion of the drug is described, as well as any precautions associated with administration.
Compatibility and stability information is described under the Stability section toward the end of the monograph.Reconstitution
For injectable drugs and other dosage forms requiring reconstitution, this subsection describes the recommended methods.Dilution
For injectable drugs and other dosage forms requiring further dilution, this subsection describes the recommended methods.Rate of Administration
For injectable drugs and other dosage forms, this subsection describes the recommended rates of administration (e.g., for direct IV injection, for IV Infusion).
The Dosage subsection describes recommended and alternative dosage schedules for each dosage form and route of administration, age of the patient, and condition being treated.
Information in this subsection is divided by age, indication, and route.
When applicable, dosage equivalencies are described (e.g., dosage of fosphenytoin is expressed in terms of phenytoin equivalents [PEs]).
When available and applicable, specific dosages for children, geriatric or debilitated patients, and patients with renal and/or hepatic impairment are described.
The initial, maintenance, and maximum (prescribing limits) dosages are given.
Occasionally, when use of a fixed-dosage combination preparation or concomitant use of the drug with another drug is considered rational, specific regimens may be described.Pediatric Patients
Describes age-specific dosages from the neonatal period through adolescence.
Dosages are further subdivided by specific indications (conditions/diseases).
Dosages for specific indications are subdivided further by specific routes of administration.Adults
Describes specific dosages for adults. Special dosages that apply to elderly adults are described under the Geriatric Patients subsection of Special Populations under Dosage.
Dosages are further subdivided by specific indications (conditions/diseases).
Dosages for specific indications are subdivided further by specific routes of administration.Special Populations
When available and applicable, specific dosages for special populations (e.g., hepatic impairment, renal impairment, geriatric patients) are described in appropriately headed subsections.Prescribing Limits
When available and applicable, maximum recommended dosages for specific patient populations (e.g., age groups), routes of administration, and uses are described.
Includes information about contraindications, warnings, major toxicities, sensitivity reactions, general precautions, precautions for specific populations (e.g., pregnancy, fetal/neonatal morbidity and mortality, lactation, pediatric use, geriatric use, hepatic impairment, renal impairment), and common adverse effects.
The Cautions section describes any special care to be taken by practitioners and/or patients for safe and effective use of the drug and describes serious adverse effects and potential safety hazards, limitations on use imposed by them, and actions that should be taken if they occur. Those situations or conditions for which the drug should not be used because the risk clearly outweighs any possible benefit also are described.
Because precautionary information about a drug frequently changes, www.ahfsdruginformation.com (see the Preface for details) and/or the manufacturer’s labeling should be reviewed periodically.
The pregnancy precautions follow FDA’s lettered categories (A, B, C, D, or X), as stated in the manufacturer’s labeling. Because of the summary outline format of Essentials™, only the letter designation usually appears. Following are definitions of the categories:
Category A: Adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester and there is no evidence of risk in later trimesters. If the drug were used during pregnancy, the possibility of fetal harm appears remote.
Category B: Either animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women or animal reproduction studies have shown an adverse effect (other than on fertility) but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester and there is no evidence of risk in later trimesters. In either case, the drug should be used during pregnancy only when clearly needed.
Category C: Either animal reproduction studies have revealed evidence of an adverse fetal effect and there are no adequate and well-controlled studies in pregnant women or animal reproduction studies have not been performed and it is not known whether the drug can cause fetal harm when administered to pregnant women. In the first case, the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. In the latter case, the drug should be used during pregnancy only when clearly needed.
Category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or postmarketing experience or studies in humans, but the potential benefits from use of the drug in pregnant women may be acceptable in certain conditions despite the possible risks to the fetus. The drug should be used during pregnancy only in life-threatening situations or severe disease for which safer drugs cannot be used or are ineffective. When the drug is administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus.
Category X: The drug may (can) cause fetal toxicity when administered to pregnant women based on animal or human studies demonstrating fetal abnormalities or positive evidence of human fetal risk from adverse reaction data from investigational or postmarketing experience, or both, and the risk of use of the drug during pregnancy clearly outweighs any benefit (e.g., safer drugs or alternative therapies are available). Since the risks clearly outweigh any possible benefits in women who are or may become pregnant, the drug is contraindicated in such women. If the drug is inadvertently administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus.Lactation
A description of whether the drug is distributed into milk is included when available, and any associated precautions regarding use of the drug in lactating women are described. Effects of the drug on lactation and/or the nursing infant also are described.Pediatric Use
Describes those pediatric age groups for which safety and/or efficacy of the drug have not been established from adequate and well-controlled studies. Risks and limitations associated with use of the drug in pediatric age groups also are described.Geriatric Use
Describes precautionary information associated with the drug in geriatric individuals and provides some perspective regarding study and experience in this population, including factors that may affect response and tolerance. For example, information on age-dependent pharmacokinetics of the drug would be described within the Pharmacokinetics section and that on age-specific dosage recommendations would be described in the Dosage and Administration section of the monograph.
Because of the relative lack of well-published, geriatric-specific information on many drugs and relative newness of FDA regulations requiring US drug manufacturers to specifically include such information in their labeling, a specific subsection for Geriatric Uses may be absent in a given monograph. In addition to the Geriatrics Uses subsection, geriatric information also may be described in the Geriatric Patients subsection of Special Populations under Dosage as well as within other appropriate sections (e.g., Pharmacokinetics) of the monograph.Hepatic Impairment
Describes specific precautions applicable to patients with impaired hepatic function.
Recommendations for specific adjustment to dosage are described in the Special Populations subsection of Dosage.Renal Impairment
Describes specific precautions applicable to patients with impaired renal function.
Recommendations for specific adjustment to dosage are described in the Special Populations subsection of Dosage.
Common Adverse Effects
Adverse reactions are undesirable effects, reasonably associated with use of the drug, that may occur as part of its pharmacologic action or may be unpredictable in occurrence. The common adverse effects subsection is not intended to be all inclusive. Potentially serious adverse effects usually are described under the Warnings and Precautions subsections under specific headed topics.
Describes clinically important drug/drug, drug/food, and drug laboratory test interactions, including adverse and therapeutically useful interactions. The mechanism of the interaction, associated clinical importance, precautions to be observed, and management of the interaction may be described briefly in the accompanying tables.
The Interactions tables list information alphabetically by interacting drug or drug class, food (usually simply under food; occasionally specific food types [e.g., grapefruit juice]), and test (under Test and then alphabetically by specific test name).
Generally, potential interactions supported only by animal or in vitro data are not described. Occasionally, theoretical interactions are presented because of the likelihood of their occurrence (e.g., based on evidence from similar drugs) or the potential severity of the effect should it occur.
Information on physical and/or chemical incompatibility of parenteral drugs and solutions is described in the Compatibility section of Stability.
Describes absorption, distribution, and elimination (biotransformation and excretion) characteristics of a drug.
The Absorption subsection includes key information on extent (bioavailability) and rate of absorption by usual routes of administration and factors (e.g., product formulation) that might influence them. Applicable comparative information on doses, dosage forms, and routes of administration may be included. Information on serum concentrations achieved and on the period of time for onset, peak, and duration of pharmacologic and/or therapeutic effect also may be included, even when an absorption phase per se does not occur (e.g., following IV administration). Ranges for therapeutic and/or toxic concentrations (e.g., plasma, serum) of the drug are described when established.
The Distribution subsection describes key information on the usual distribution of the drug into body tissue and fluids. Information describing the drug’s propensity to cross the blood-brain barrier and placenta and to distribute into milk is included. Protein binding characteristics are presented.
The Elimination subsection describes key information on the biotransformation and excretory characteristics of the drug. Information on elimination half-life and factors influencing it, clearance, site and extent of biotransformation, metabolic products and their activities, and routes of elimination from the body (e.g., urine, feces via bile) and factors affecting them is included. The effect of peritoneal dialysis and hemodialysis on elimination of the drug also is discussed.
Describes extent of systemic absorption of a drug from various routes of administration (e.g., oral, IM, transdermal, buccal).
Describes whether the drug undergoes first-pass metabolism.
Describes whether a drug is a prodrug.Onset
Describes the onset of various effects of the drug, specific to various routes of administration when available.Duration
Describes the duration of various effects of the drug, specific to various routes of administration when available.Food
Describes the effect of food on absorption of the drug.Plasma Concentrations
Describes attainment of plasma concentrations for various routes of administration.Special Populations
Describes specific absorption characteristics in special populations.
Describes distribution of the drug into various tissues (e.g., placenta, eyes, organs) and fluids (e.g., breast milk, CSF).Plasma Protein Binding
Describes extent of drug binding to plasma proteins (e.g., albumin, α1-acid glycoprotein)
Describes principal metabolic pathways for the drug and any associated pharmacologic or toxic activity.Elimination Route
Describes the principal routes of elimination for the drug (e.g., urine, feces, expired air).Half-life
Describes the elimination half-lives for the drug.Special Populations
Describes the effects of alterations in elimination half-life of the drug secondary to renal and hepatic impairment.
Applicable stability information such as the effect of heat, light, moisture, air, and freezing may be described. Stability information about reconstituted and/or diluted preparations is provided. Physical and/or chemical compatibility information is included.
Describes storage requirements (i.e., recommended environmental storage conditions) for products and formulations. Also describes storage conditions and associated stability for reconstituted and diluted preparations.
Describes compatibility information for parenteral preparations, including commercially available injections and reconstituted and diluted solutions.
The information may include a general discussion and several tables organized by solution compatibility, drug compatibility, and Y-site compatibility. Within each table, information is subdivided according to whether the drug is compatible, incompatible, or variably compatible.
Information in the compatibility section summarizes complex information from multiple sources in an easy-to-use, reliable format. Designed with the input of nurses and pharmacists, the tables greatly simplify quick location of specific information on the compatibility of parenteral drugs when diluted with common IV infusion solutions, admixed with other drugs in IV solutions, or run through a common Y-site. The absence of specific solutions or drugs does not imply compatibility or incompatibility.
Additional detailed compatibility information on injectable drugs is available in specialized references such as the Handbook on Injectable Drugs (HID, available from the ASHP; go to www.ashp.org for details). Solutions and drugs are listed as variably compatible because their compatibility differed based on environmental (e.g., exposure to various light and temperature conditions) and other (e.g., concentration, pH, formulation) conditions or there was conflicting evidence under similar conditions. It is particularly important to consult such specialized references when the solution or drug compatibility is listed as variable, since details on the conditions under which they are likely to be compatible versus incompatible will be described there.
Only a small amount of information on compatibility of drugs mixed in the same syringe is included; consult specialized references for additional information.
A cross-reference at the beginning of the compatibility section advises users that information on systemic interactions of drugs is described in the Interactions section.Solution Compatibility
Lists alphabetically by IV infusion solution name (under 3 separate portions of the table) solutions in which the drug is compatible, incompatible, or variably compatible.Drug Compatibility
Lists alphabetically by admixed drug (under 3 separate portions of the table) combinations that are compatible, incompatible, or variably compatible when admixtures are prepared in common IV solutions.Y-site Compatibility
Lists alphabetically by admixed drug (under 3 separate portions of the table) combinations that are compatible, incompatible, or variably compatible when flowing through the common portion of IV administration set below the Y-site. Consult specialized references for additional details.
Actions and Spectrum
Information is presented in a bulleted format.
Includes a brief statement of pharmacologic activity and/or mechanism of action, often compared with other similar drugs, for the purpose of orientation and introduction. More specific brief descriptions of important pharmacologic activities and effects follow.
For anti-infectives, the important in vitro spectra of activity is summarized.
In general, nomenclature for microorganisms follows that presented in the current edition of Bergey’s Manual of Systematic Bacteriology and the “Approved Lists of Bacterial Names” published in the International Journal of Systematic Bacteriology. Other standard sources, as described by the American Society for Microbiology in the January issue of Antimicrobial Agents and Chemotherapy, also are used.
Advice to Patients
Information is presented in a bulleted format.
Includes important information to advise patients and/or their caregivers concerning risks of therapy, special instructions for use and monitoring, and other guidance.
It generally is important that all patients be advised to inform their clinicians about concomitant therapies and diseases and for women of childbearing potential if they are or plan to become pregnant or to breast-feed.
The Cautions section and any Boxed Warning also should be consulted for other precautionary information that may be relevant to the patient and/or their caregivers.
Detailed product descriptions in the style of AHFS Drug Information.
Lists commercially available preparations of the drug. Combination preparations are described under a separate heading (e.g., Aspirin Combinations) following the appropriate single-entity subsection (e.g., Aspirin). Important excipients (e.g., preservatives, tartrazine, sulfites) contained in the preparation or additional descriptive information about the preparation (e.g., alcohol content) may be included parenthetically following the brand (trade) name.
Preparations are described under the appropriate heading by USAN or other generic (nonproprietary) name.
Preparations are listed hierarchically by route of administration (alphabetically), dosage form (alphabetically), and strength (in order of increasing strength). When potency is described in terms other than those listed in the drug heading (e.g., potency of cefotaxime sodium is expressed in terms of cefotaxime), the labeled moiety is described parenthetically after the strength [e.g., 1 g (of cefotaxime)].
Route of administration and dosage form listings may be modified (e.g., Injection, for IM use only; Tablets, chewable; Capsules, extended-release).
Following each preparation description, the trade (proprietary) names are listed alphabetically and include the corresponding manufacturers. Generally, multiple-source preparations that are available by generic (nonproprietary) name do not include the manufacturers/labelers; these preparations are described as being “available generically.”
When established by USP, pharmacy equivalent names (PENs) (e.g., co-careldopa for levodopa and carbidopa) are listed parenthetically alongside the corresponding combination heading. PENs are short and simple names that can be used for convenience by practitioners when it would be impractical to use the complete nonproprietary combination name. PENs are informational rather than official (USP/NF), but are offered by USP as standardized terms intended to discourage the proliferation of trivial names and undefined abbreviations for combinations. This abbreviated nomenclature was pioneered by the British Pharmacopoeia (BP) and subsequently adopted by USP.
Generally, dosage forms used in the Preparations sections are the pharmaceutical dosage forms described in USP. (See the current edition of the United States Pharmacopeia.) Several dosage forms (i.e., elixir, extract, fluidextract, spirit, tincture) are used only when the preparation is official (USP or NF). Solution generally is used to describe all liquid preparations of dissolved drug, regardless of solvent; although syrups occasionally are official (USP or NF), these are listed as solutions and syrup is included only as part of the proprietary name.
Applicable legal descriptions (e.g., drugs subject to control under the Federal Controlled Substances Act of 1970) are included (i.e., C-II, C-III, C-IV, and C-V).
Certain monographs in AHFS DI EssentialsTM are designated as AHFSfirstReleases™. This designation appears in a boldface notice at the beginning of the Cautions section for the respective monograph. AHFSfirstReleases™ disseminate timely information on new molecular entities (NMEs) in a expedited, concise format as soon as possible after FDA approval; the principal limitation is availability of final labeling from the manufacturer.
AHFSfirstReleases™ are concise descriptions about new molecular entities (NMEs) that include information drawn principally from the manufacturer’s labeling (package insert); however, the descriptions are not intended to be comprehensive. When additional information on such drugs is needed before publication of a more detailed monograph, the manufacturer’s labeling should be consulted.
AHFSfirstReleases™ are intended to provide subscribers with concise descriptions on NMEs that can answer typical basic questions about newly approved drugs. As such, the descriptions are limited to only basic information on the drugs, including brief introductory descriptions (chemical and pharmacologic) of the type of drug, its labeled uses and associated dosages, product availability, and contraindications. As a result, the AHFSfirstReleases™ do not provide full disclosure about the respective drugs, and therefore it is essential that the manufacturer’s labeling be consulted for more detailed information on usual cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity.